Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis
NCT03844932 is registered in ClinicalTrials.gov with Sublimity Therapeutics Holdco Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis
- Lead sponsor
- Sublimity Therapeutics Holdco Limited
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 24, 2019
- Completion date
- April 14, 2021
- Enrollment
- 235 (actual)
- Sites
- 89
Conditions
As the registry lists them; a condition with its own page is linked.